[
  {
    "ts": "2025-09-25T16:11:14+00:00",
    "headline": "BMS expands DTC offering with Sotyktu addition",
    "summary": "Patients will now be able to access Eliquis and Sotyktu for significantly cheaper than their current list prices.",
    "url": "https://www.pharmaceutical-technology.com/news/bms-direct-to-consumer-sotyktu-expansion/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "5596e339-742f-3e27-ae90-5882dffe809c",
      "content": {
        "id": "5596e339-742f-3e27-ae90-5882dffe809c",
        "contentType": "STORY",
        "title": "BMS expands DTC offering with Sotyktu addition",
        "description": "",
        "summary": "Patients will now be able to access Eliquis and Sotyktu for significantly cheaper than their current list prices.",
        "pubDate": "2025-09-25T16:11:14Z",
        "displayTime": "2025-09-25T16:11:14Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/25c61559a46900e2367ed838011288b4",
          "originalWidth": 1440,
          "originalHeight": 900,
          "caption": "BMS' Patient Connect platform will enable customers to purchase Sotyktu for more than 80% less than the drug's current list price. Image credit: Rosemarie Mosteller via Shutterstock.com.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fsYqyGpKmPeu.cfCG5aKJw--~B/aD05MDA7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/25c61559a46900e2367ed838011288b4.cf.webp",
              "width": 1440,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CeyTo4BYsDxj67v6Jkxvwg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/25c61559a46900e2367ed838011288b4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/bms-direct-to-consumer-sotyktu-expansion/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bms-expands-dtc-offering-sotyktu-161114102.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-25T14:05:57+00:00",
    "headline": "PGIM Jennison Health Sciences Fund Sold its Position in Bristol-Myers Squibb Co. (BMY) in Q2",
    "summary": "PGIM, an investment management company, released its “PGIM Jennison Health Sciences Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equities in the second quarter of 2025 experienced significant volatility, as the steep sell-off that initiated at the beginning of the quarter ultimately led to a strong recovery. The S&P […]",
    "url": "https://finance.yahoo.com/news/pgim-jennison-health-sciences-fund-140557638.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "31f1bba6-7890-3c89-aec1-b52fbd892368",
      "content": {
        "id": "31f1bba6-7890-3c89-aec1-b52fbd892368",
        "contentType": "STORY",
        "title": "PGIM Jennison Health Sciences Fund Sold its Position in Bristol-Myers Squibb Co. (BMY) in Q2",
        "description": "",
        "summary": "PGIM, an investment management company, released its “PGIM Jennison Health Sciences Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equities in the second quarter of 2025 experienced significant volatility, as the steep sell-off that initiated at the beginning of the quarter ultimately led to a strong recovery. The S&P […]",
        "pubDate": "2025-09-25T14:05:57Z",
        "displayTime": "2025-09-25T14:05:57Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/5f20cdc6e9694860a75fcf45a32618af",
          "originalWidth": 768,
          "originalHeight": 430,
          "caption": "Bristol-Myers Squibb Company’s (BMY) Dividend Track Record: A Must-Have for a Dividend Stock Portfolio",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WZTRF839CsopxcOyHv57Ug--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/5f20cdc6e9694860a75fcf45a32618af.cf.webp",
              "width": 768,
              "height": 430,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4s_q4.P5esjmvi8c7wRNPQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/5f20cdc6e9694860a75fcf45a32618af.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pgim-jennison-health-sciences-fund-140557638.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pgim-jennison-health-sciences-fund-140557638.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "CELG-RT"
            },
            {
              "symbol": "^SPX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-25T10:59:00+00:00",
    "headline": "Bristol Myers Squibb Builds on Eliquis® (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu® (deucravacitinib)",
    "summary": "PRINCETON, N.J., September 25, 2025--Bristol Myers Squibb Builds on Eliquis® (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu®...",
    "url": "https://finance.yahoo.com/news/bristol-myers-squibb-builds-eliquis-105900912.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "01c04c6e-e08c-343f-a4d7-aa404d734196",
      "content": {
        "id": "01c04c6e-e08c-343f-a4d7-aa404d734196",
        "contentType": "STORY",
        "title": "Bristol Myers Squibb Builds on Eliquis® (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu® (deucravacitinib)",
        "description": "",
        "summary": "PRINCETON, N.J., September 25, 2025--Bristol Myers Squibb Builds on Eliquis® (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu®...",
        "pubDate": "2025-09-25T10:59:00Z",
        "displayTime": "2025-09-25T10:59:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/a1ea6c187379f0852023c0f76e0fd076",
          "originalWidth": 1497,
          "originalHeight": 206,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ldqOWsR28AZQlLDuAv4DWg--~B/aD0yMDY7dz0xNDk3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a1ea6c187379f0852023c0f76e0fd076.cf.webp",
              "width": 1497,
              "height": 206,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Gnifst8CpQZ3lcCFsM_WsQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a1ea6c187379f0852023c0f76e0fd076.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-builds-eliquis-105900912.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "CELG-RT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]